Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMVT-1402 in Active, Difficult to Treat, ACPA-Positive Rheumatoid Arthritis
NCT06754462Phase 2Active, not recruiting
- Sponsor
- Immunovant, Inc.
- Start
- Jan 2025
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of IMVT-1402 in rheumatoid arthritis (RA), sponsored by Immunovant, Inc.. Started Jan 2025; status: active, not recruiting.
02
Drugs
IMVT-1402
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06754462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06754462.